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Abstract 
 
Trypanosomosis is a disease of medical and veterinary importance, mainly distributed in 
tropical areas of Africa, Latin America and Asia. Some Trypanosoma species are typically pathogenic 
for animals, such as Trypanosoma vivax, T. congolense, T. evansi etc, and others are zoonotic, such as 
the agents of sleeping sickness in Africa (Trypanosoma brucei ssp.), or Chagas disease in Latin 
America (T. cruzi). Beside these 2 “typical” human trypanosomes, there is a growing number of 
reported “atypical” human infections due to Trypanosoma evansi, a livestock parasite, or 
Trypanosoma lewisi, a rat commensal, especially in Asia. Drugs available for the treatment of 
T. brucei ssp in humans are obviously of choice for the control of T. evansi because it is derived from 
T. brucei lineage; indeed, in 2 recent cases of human infection by T. evansi, successful treatments 
were obtained using suramine. However, concerning T. lewisi, there is a need to determine the 
efficacy of trypanocidal drugs for the treatment in humans. In a recent study, pentamidine and 
fexinidazole were shown to have the best efficacy against one stock of T. lewisi in rats, they have 
thus been explored amongst others.  
In order to explore efficient trypanocidal drugs, attempts were made to treat groups of 3 rats 
experimentally infected by T. lewisi, using low and high doses of the available human and veterinary 
trypanocidal drugs: diminazen aceturate (DA; 14 and 28 mg/kg), isometamidium chloride (IMC: 2 and 
4 mg/kg), quinapyramine sulfate and chloride (QSC; 8.3 and 16.6 mg/kg), cymelarsan (Cym; 0.5 and 1 
mg/kg), suramine (20 and 40 mg/kg), pentamidine diisetionate (Pt: 8 and 16 mg/kg), eflornitine 
hydrochloride (Efl; 800 and 16000 mg/kg), nifurtimox (Nt; 30 and 60mg/kg), benznidazole (Bz; 20 and 
40 mg/kg) and fexinidazole (Fex; 200 mg/kg). At the exception of Nt, Bz and Fex which were 
administered perorale route, all drugs were intramuscularly injected. All treatments at all doses 
failed to clear parasites from rat’s blood.  
To confirm the potential efficacy of fexinidazole, a mixed infection protocol was set up in 
cyclophosphamide immunosuppressed rats. Animals were infected successively by T. lewisi and 
T. evansi, and received 10 daily peroral administrations of 200 mg/kg fexinidazole or 0.5 mg/kg Cym. 
T. evansi was cleared from the rat’s blood within 24 to 48 hours; however, the treatment did not 
affect T. lewisi which remained in high number in the blood until the end of the experiment. Results 
are discussed and further studies suggested. Because of its potential as an emerging parasite in 
humans, identifying efficient trypanocides against T. lewisi is required. 
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